IL17A and experimental autoimmune encephalomyelitis: On the other hand, Fingolimod (FTY-720, Gilenya), the first oral disease-modifying drug approved by the US Food and Drug Administration (FDA) for treating RRMS in 2010 (Kappos et al. 2010), has a marked S1PR1-dependent therapeutic effect on murine experimental autoimmune encephalomyelitis by reducing infiltration of IL-17-producing T cells into the spinal cord (Chiba et al. 2011).